Vascular Graft Infections: An update
| dc.contributor.author | Gharamti, Amal A. | |
| dc.contributor.author | Kanafani, Zeina A. | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.department | Division of Infectious Diseases | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:52:22Z | |
| dc.date.available | 2025-01-24T11:52:22Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Vascular graft infection is a devastating complication of vascular reconstructive surgery. The infection can occur early in the postoperative period and is largely due to intraoperative contamination or by contiguous extension from a nearby infection. It can also occur years after implantation. Staphylococci remain the most common organisms and biofilm production makes eradication difficult. Factors commonly reported to predispose to vascular graft infection are periodontal disease, nasal colonization with Staphylococcus aureus, bacteremia, certain graft characteristics, diabetes mellitus, postoperative hyperglycemia, location of the incision, wound infection, and emergency procedure. Management consists of antibiotic and surgical therapy. Preventive methods are described. © 2018 Elsevier Inc. | |
| dc.identifier.doi | https://doi.org/10.1016/j.idc.2018.06.003 | |
| dc.identifier.eid | 2-s2.0-85053715486 | |
| dc.identifier.pmid | 30241716 | |
| dc.identifier.uri | http://hdl.handle.net/10938/31055 | |
| dc.language.iso | en | |
| dc.publisher | W.B. Saunders | |
| dc.relation.ispartof | Infectious Disease Clinics of North America | |
| dc.source | Scopus | |
| dc.subject | Bacteremia | |
| dc.subject | Biofilm | |
| dc.subject | Staphylococci | |
| dc.subject | Vascular graft infection | |
| dc.subject | Vascular reconstructive surgery | |
| dc.subject | Anti-bacterial agents | |
| dc.subject | Bacterial infections | |
| dc.subject | Humans | |
| dc.subject | Vascular grafting | |
| dc.subject | Alpha toxin | |
| dc.subject | Cefazolin | |
| dc.subject | Cefuroxime | |
| dc.subject | Clindamycin | |
| dc.subject | Gentamicin | |
| dc.subject | Rifampicin | |
| dc.subject | Vancomycin | |
| dc.subject | Virulence factor | |
| dc.subject | Antiinfective agent | |
| dc.subject | Antibiotic prophylaxis | |
| dc.subject | Antibiotic therapy | |
| dc.subject | Aortointestinal fistula | |
| dc.subject | Artery graft | |
| dc.subject | Bacterial colonization | |
| dc.subject | Blood vessel graft | |
| dc.subject | Clinical classification | |
| dc.subject | Clinical feature | |
| dc.subject | Coagulase negative staphylococcus | |
| dc.subject | Computed tomographic angiography | |
| dc.subject | Cryopreservation | |
| dc.subject | Diabetes mellitus | |
| dc.subject | Disease association | |
| dc.subject | Disease predisposition | |
| dc.subject | Drug effect | |
| dc.subject | Echocardiography | |
| dc.subject | Emergency surgery | |
| dc.subject | Excision | |
| dc.subject | Graft infection | |
| dc.subject | Human | |
| dc.subject | Hyperglycemia | |
| dc.subject | Incision | |
| dc.subject | Infection prevention | |
| dc.subject | Methicillin susceptible staphylococcus aureus | |
| dc.subject | Nonhuman | |
| dc.subject | Pathogenesis | |
| dc.subject | Periodontal disease | |
| dc.subject | Positron emission tomography-computed tomography | |
| dc.subject | Postoperative complication | |
| dc.subject | Postoperative period | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Review | |
| dc.subject | Risk factor | |
| dc.subject | Staphylococcal bacteremia | |
| dc.subject | Tissue engineering | |
| dc.subject | Treatment planning | |
| dc.subject | Vascular disease | |
| dc.subject | Wound care | |
| dc.subject | Wound infection | |
| dc.subject | Bacterial infection | |
| dc.subject | Microbiology | |
| dc.title | Vascular Graft Infections: An update | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1